Home » Stocks » CYDY

CytoDyn, Inc. (CYDY)

Stock Price: $2.67 USD 0.00 (0.00%)
Updated November 25, 3:59 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.52B
Revenue (ttm) n/a
Net Income (ttm) -139.07M
Shares Out 570.75M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE 10.81
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $2.67
Previous Close $2.67
Change ($) 0.00
Change (%) 0.00%
Day's Open 2.67
Day's Range 2.63 - 2.69
Day's Volume 1,180,182
52-Week Range 0.261 - 10.01

More Stats

Market Cap 1.52B
Enterprise Value 1.54B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 570.75M
Float 499.88M
EPS (basic) -0.31
EPS (diluted) -0.30
FCF / Share -0.17
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta -0.87
PE Ratio n/a
Forward PE 10.81
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 525.80
Revenue n/a
Operating Income -87.58M
Net Income -139.07M
Free Cash Flow -94.66M
Net Cash -14.19M
Net Cash / Share -0.02
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -97.97%
ROE n/a
ROIC 1,977.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.00*
Low
4.00
Current: $2.67
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue----------
Operating Income-74.65-55.85-45.92-27.33-21.18-19.60-8.11-7.99-7.46-3.70
Net Income-124-56.19-50.15-25.76-25.70-25.09-12.43-9.57-7.47-3.72
Shares Outstanding42127217513895.4458.3846.9029.9424.6221.08
Earnings Per Share-0.30-0.21-0.29-0.19-0.27-0.43-0.27-0.32-0.31-0.18
Operating Cash Flow-68.80-50.47-29.90-26.73-24.81-12.02-7.39-3.39-4.39-1.82
Capital Expenditures-0.04-0.03--0.01-0.01-0.02-0.02---
Free Cash Flow-68.84-50.49-29.90-26.74-24.82-12.04-7.41-3.40-4.39-1.83
Cash & Equivalents14.293.471.231.789.641.054.890.600.281.04
Total Debt15.358.24-1.06-4.272.341.990.080.16
Net Cash / Debt-1.06-4.771.230.729.64-3.222.55-1.390.200.88
Assets50.5120.874.908.0613.794.688.434.161.071.99
Liabilities53.0029.7918.069.163.5815.374.514.385.047.00
Book Value-2.48-8.91-13.16-1.1010.21-10.693.92-0.22-3.97-5.01
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CytoDyn, Inc.
Country United States
Employees 19
CEO Nader Z. Pourhassan

Stock Information

Ticker Symbol CYDY
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: CYDY

Description

CytoDyn, a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.